Neoantigen-Major Histocompatibility Complex-T cell receptor complex (NeoAg-MHC-TCR complex)

The Neoantigen-Major Histocompatibility Complex-T cell receptor (NeoAg-MHC-TCR) complex is a fundamental unit of the adaptive immune system's ability to recognize and eliminate malignant cells. Neoantigens are novel peptides derived from somatic mutations unique to a patient's tumor, which are processed and presented on the cell surface by Major Histocompatibility Complex (MHC) Class I or II molecules (Source: NIH/NCI). These complexes are then recognized by specific T cell receptors (TCRs) on the surface of CD8+ or CD4+ T cells, respectively, initiating a targeted immune response against the cancer (Source: PubMed: 28723894). Because neoantigens are not expressed in normal tissues, they represent highly specific therapeutic targets with a lower risk of central tolerance compared to tumor-associated self-antigens. Therapeutic strategies leveraging this complex include personalized neoantigen vaccines, which prime the patient's own immune system to recognize these unique markers, and adoptive cell therapies like TCR-engineered T cells (TCR-T), which provide the patient with a population of T cells pre-programmed to attack the neoantigen-MHC complex (Source: Nature Reviews Cancer: 17, 209–222). The success of these therapies depends heavily on the accurate identification of immunogenic neoantigens through genomic sequencing and the prediction of their binding affinity to the patient's specific HLA alleles. While highly promising for precision oncology, challenges remain regarding the heterogeneity of tumor mutations and the potential for tumors to evade detection by downregulating MHC expression (Source: PubMed: 30610225).

Other names

Tumor-specific neoantigen-MHC complexNeoepitope-HLA-TCR complexPatient-specific neoantigen peptidesTSA-MHC-TCR complexTumor-specific antigen-MHC-TCR complex

Drugs targeting this complex function by either delivering the neoantigen peptide (vaccines) to be processed and presented by MHC molecules, or by providing engineered T cells (TCR-T) that express a specific TCR designed to recognize the patient's unique neoantigen-MHC complex. This interaction triggers the activation of cytotoxic T lymphocytes, leading to the selective destruction of tumor cells expressing the specific neoantigen (Source: PubMed: 31048553, Nature: 547, 217–221).